Quick Answer
Sarepta Therapeutics, Inc. reported Net Income Loss of -$713.41 million for the year ending 2025.
- Sarepta Therapeutics, Inc. showed a decrease of -403.3% in Net Income Loss from 2024 to 2025.
- This data is from Sarepta Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 2, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 17 years of available data (2009 to 2025), Sarepta Therapeutics, Inc.'s Net Income Loss has declined by 2,735.6%.
- Historical annual values: Fiscal year 2025: -$713.41 million | Fiscal year 2024: $235.24 million | Fiscal year 2023: -$535.98 million | Fiscal year 2022: -$703.49 million | Fiscal year 2021: -$418.78 million | Fiscal year 2020: -$554.13 million | Fiscal year 2019: -$715.08 million | Fiscal year 2018: -$361.92 million | Fiscal year 2017: -$50.69 million | Fiscal year 2016: -$267.27 million | Fiscal year 2015: -$220.03 million | Fiscal year 2014: -$135.79 million | Fiscal year 2013: -$111.99 million | Fiscal year 2012: -$121.29 million | Fiscal year 2011: -$2.32 million | Fiscal year 2010: -$32.18 million | Fiscal year 2009: -$25.16 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: